The Food and Drug Administration (FDA) has rejected Elon Musk's application to conduct human trials of his Neuralink brain implant device over safety concerns. Seven current and former [.]
On at least four occasions since 2019, Elon Musk has predicted that his medical device company, Neuralink, would soon start human trials of a revolutionary brain implant to treat intractable conditions such as paralysis and blindness. Yet the company, founded in 2016, didn't seek permission from the US Food and Drug Administration (FDA) until early 2022 and the agency.
The Global Fund invites manufacturers of pharmaceutical products to submit an Expression of Interest (EoI) to have their products evaluated by the Expert Review Panel for pharmaceutical products (ERP).